Keefe Bruyette reiterates Goldman Sachs stock rating at $1,000 target By Investing.com

Keefe, Bruyette & Woods kept a Market Perform rating on Goldman Sachs with a $1,000 price target, while raising 2026 and 2027 earnings estimates by 1%. Goldman also posted Q1 2026 EPS of $17.55 versus $16.47 expected, though adjusted EPS of $14.64 missed some estimates and the CET1 ratio declined, contributing to modest stock underperformance versus universal bank peers by 300-400 bps. The company also commented on a 3.6% drop in U.S. existing home sales in March due to weather, underscoring mixed macro conditions.

Analysis

GS is still priced like a quality compounder, but the market is currently paying for an earnings inflection that may be more cyclical than durable. The key second-order issue is that capital markets strength tends to pull multiple upward faster than balance-sheet-heavy revenue can re-rate, so any disappointment in trading or CET1 can compress the premium quickly. In other words, the stock can look expensive even when the underlying business is merely normalizing rather than deteriorating.

The broader winner set is not just GS competitors, but also firms with more predictable fee mix and less capital drag; those names should be better insulated if the market starts to punish “beat but not enough” quarters. On the flip side, banks with higher sensitivity to trading volatility and capital return stories can see amplified downside because investors will use GS as a read-through on whether the current bank rally was too crowded. The low PEG is only helpful if estimate revisions keep broadening for several quarters; a single quarter of softer flow/revenue can reset that narrative.

The contrarian take is that the negative share reaction may be more about positioning than fundamentals. If expectations were already elevated, modest estimate revisions and still-constructive analyst revisions suggest the easier path may be for the stock to grind higher over 1-2 quarters, especially if capital markets stay active. The risk is that the next catalyst is not earnings growth but capital deployment: if CET1 remains under pressure, buybacks may be the first thing investors discount, limiting upside even if EPS trends improve.

Near term, the setup is a classic post-earnings digestion trade: weak holders may exit over the next few sessions, but fundamentals likely matter more into the next 1-2 print cycle than the immediate tape. If the stock fails to reclaim relative strength versus universal banks within two weeks, that argues the market is de-rating the multiple rather than the earnings stream. Conversely, a quick recovery in relative performance would confirm the move was positioning-driven and not a thesis break.

Key Decisions for Investors

• Hold/accumulate GS on a 1-3 month horizon only on relative-strength confirmation vs KBE/XLF; if GS reclaims prior post-earnings support, the risk/reward shifts back toward a 2:1 upside/downside setup.
• Pair trade: long GS / short a higher-multiple universal bank basket over 4-8 weeks if you believe capital markets revenue remains firm; GS has more operating leverage to a stable deal backdrop, but only if CET1 fears stay contained.
• If already long GS, buy short-dated downside protection into the next 2-4 weeks rather than selling stock outright; the main risk is multiple compression from any follow-on revision to capital return expectations.
• For event-driven exposure, wait for the next analyst revision cycle before adding size; the stock is vulnerable to one more estimate reset, but a broadening of positive revisions could support a move toward the current consensus target over 3-6 months.
• Avoid chasing the move immediately after earnings; require either a rebound in relative performance or a stabilization in capital ratios, because the risk/reward is poor if the market is shifting from 'great bank' to 'good bank' valuation.